Name : WANG, Xin 王鑫
Title :

Associate Professor

Home Department :  Surgery
Email :
Phone Number (852) 3505 2746



Dr. Xin Wang obtained his PhD in 2014 from the University of Cambridge Department of Oncology and Cancer Research UK Cambridge Institute. From 2013 to 2015, he did postdoctoral research at the Department of Biomedical Informatics, Harvard Medical School. He joined City University of Hong Kong in March 2015 and was promoted to Associate Professor and Associate Head at the Department of Biomedical Sciences. In 2021, he joined the Department of Surgery, Chinese University of Hong Kong, as an Associate Professor, leading the Division of Biomedical Informatics. He is currently a member of the academic committee of Guangdong Key Laboratory of Human Disease Genomics, and a consultant for Shanghai Artificial Intelligence Laboratory Smart Medical Research Center.

Dr. Wang’s major research field is Biomedical Informatics with a special focus on clinical translations. Since 2012, he has been focusing on mechanistic and translational research in major human diseases by developing novel methodologies integrating bioinformatics, systems biology, machine learning and artificial intelligence. In collaboration with molecular biologists and experimental oncologists, he is especially fascinated by the research into the mechanisms related to cancer development and metastasis. Together with clinicians, his group has also been dedicating to preclinical and clinical studies about molecular and image-based biomarkers for cancer early detection, diagnosis, prognosis and subtyping. Dr. Wang published > 90 papers in well-known journals such as Nature Medicine, Gastroenterology, Hepatology, Annals of Surgery, Science Advances, and Nature Communications. His research is currently funded by Research Grants Council of Hong Kong, Shenzhen City and Guangdong Province.

Specialised Research Area(s):

  • Cancer Bioinformatics
  • Cancer Biology
  • Biomarker Development

Selected Publications:

1. Kandimalla R+, Wang W+, Yu F, Zhou N, Gao F, Spillman M, Moukova L, Slaby O, Salhia B, Zhou S*, Wang X*, Goel A*. OCaMIR-A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective Study, Clinical Cancer Research 2021. doi: 10.1158/1078-0432.CCR-21-0267. Epub 2021 May 25. PMID: 34035068; PMCID: PMC10327469.

2. Huang H+, Hu J+, Maryam A, Huang Q, Zhang Y, Ramakrishnan S, Li J, Ma H, Ma VWS, Cheuk W, So GYK, Wang W, Cho WCS, Zhang L, Chan KM, Wang X*, Chin YR*. Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling, Nature Communications 2021, 21:1-16.